Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
about
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition.Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice.The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
P2860
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Rationale for targeting multip ...... cardiovascular risk reduction.
@ast
Rationale for targeting multip ...... cardiovascular risk reduction.
@en
type
label
Rationale for targeting multip ...... cardiovascular risk reduction.
@ast
Rationale for targeting multip ...... cardiovascular risk reduction.
@en
prefLabel
Rationale for targeting multip ...... cardiovascular risk reduction.
@ast
Rationale for targeting multip ...... cardiovascular risk reduction.
@en
P1476
Rationale for targeting multip ...... cardiovascular risk reduction.
@en
P2093
Christie M Ballantyne
P304
14K-19K; discussion 34K-35K
P356
10.1016/J.AMJCARD.2005.08.003
P407
P577
2005-09-12T00:00:00Z